Exhibit 99.1
VBI to Present at the LD Micro Conference
Jeff Baxter, VBI’s President and CEO, has been invited to speak at theLD Micro Conference inLos Angeles, CA on December 3rd, 2014.
CAMBRIDGE, MA (November 24th, 2014) – VBI Vaccines (Nasdaq:VBIV) ("VBI") will present at the LD Micro Conference on Wednesday, December 3rd at 9:00 AM PT. The event is being held in Los Angeles, CA at the Luxe Sunset Boulevard Hotel.
At the conference, Jeff Baxter, VBI’s President and CEO, will discuss current company developments and will meet with select investors for one-on-one meetings. For additional information, visit:http://ldmicro.com/companies/vbiv/
“Having only recently made our NASDAQ debut, we are pleased to share our progress with a broader community of investors,” commented Mr. Baxter. “We continue to make progress on multiple fronts, including on the development of our lead candidate, a prophylactic Cytomegalovirus (“CMV”) vaccine.”
Following the conference, VBI’s corporate presentation will be made available in the Investor Relations section of VBI’s website:http://ir.vbivaccines.com/presentations
About VBI Vaccines, Inc.
VBI Vaccines, Inc. (“VBI”) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. VBI’s lead eVLP asset is a prophylactic Cytomegalovirus (“CMV”) vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.
Website Home:http://www.vbivaccines.com
News and Insights:http://www.vbivaccines.com/wire/
Investors:http://ir.vbivaccines.com/
CompanyContact
Jeff Baxter, President and CEO
Phone: (617) 830-3031 x125
Email: ir@vbivaccines.com
VBI Vaccines, Inc. | 222 Third Street, Suite 2241 | Cambridge, MA 02142 | 617-830-3031 | info@vbivaccines.com
Investor Contacts
Robert B. Prag, President
The Del Mar Consulting Group, Inc.
Phone: (858) 361-1786
Email: bprag@delmarconsulting.com
Scott Wilfong, President
Alex Partners, LLC
Phone: (425) 242-0891
Email: scott@alexpartnersllc.com
Forward-Looking Statement Disclosure
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of VBI. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to VBI cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, VBI will not obtain appropriate or necessary governmental approvals to market these or other potential products, VBI may not be able to obtain anticipated funding for its development projects or other needed funding, and VBI may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and VBI does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
More detailed information about VBI and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in VBI’s filings with the Securities and Exchange Commission (the “Commission”). VBI urges investors and security holders to read those documents free of charge at the Commission’s Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from VBI. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, VBI undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
VBI Vaccines, Inc. | 222 Third Street, Suite 2241 | Cambridge, MA 02142 | 617-830-3031 | info@vbivaccines.com
2
